6HJJ

Crystal structure of Aurora-A L210C catalytic domain in complex with ASDO6 ligand


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.13 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.209 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Type II Kinase Inhibitors Targeting Cys-Gatekeeper Kinases Display Orthogonality with Wild Type and Ala/Gly-Gatekeeper Kinases.

Ocasio, C.A.Warkentin, A.A.McIntyre, P.J.Barkovich, K.J.Vesely, C.Spencer, J.Shokat, K.M.Bayliss, R.

(2018) ACS Chem. Biol. 13: 2956-2965

  • DOI: 10.1021/acschembio.8b00592
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Analog-sensitive (AS) kinases contain large to small mutations in the gatekeeper position rendering them susceptible to inhibition with bulky analogs of pyrazolopyrimidine-based Src kinase inhibitors (e.g. PP1). This 'bump-hole' method has been utili ...

    Analog-sensitive (AS) kinases contain large to small mutations in the gatekeeper position rendering them susceptible to inhibition with bulky analogs of pyrazolopyrimidine-based Src kinase inhibitors (e.g. PP1). This 'bump-hole' method has been utilized for at least 85 of ~520 kinases, but many kinases are intolerant to this approach. To expand the scope of AS-kinase technology, we designed type II kinase inhibitors, ASDO2/6 (Analog-Sensitive 'DFG-Out' kinase inhibitors-2/6), that target the 'DFG-out' conformation of cysteine (Cys)-gatekeeper kinases with submicromolar potency. We validated this system in vitro against Greatwall kinase (GWL), Aurora-A kinase and Cyclin-dependent kinase-1 and in cells using M110C-GWL expressing mouse embryonic fibroblasts. These Cys-gatekeeper kinases were sensitive to ASDO2/6-inhibition, but not AS-kinase inhibitor 3MB-PP1 and vice versa. These compounds, with AS-kinase inhibitors, have the potential to inhibit multiple AS-kinases independently with applications in systems level and translational kinase research as well as the rational design of type II kinase inhibitors targeting endogenous kinases.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Aurora kinase A
A
285Homo sapiensMutation(s): 3 
Gene Names: AURKA (AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6)
EC: 2.7.11.1
Find proteins for O14965 (Homo sapiens)
Go to Gene View: AURKA
Go to UniProtKB:  O14965
Small Molecules
Ligands 4 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ACT
Query on ACT

Download SDF File 
Download CCD File 
A
ACETATE ION
C2 H3 O2
QTBSBXVTEAMEQO-UHFFFAOYSA-M
 Ligand Interaction
CL
Query on CL

Download SDF File 
Download CCD File 
A
CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
 Ligand Interaction
G7T
Query on G7T

Download SDF File 
Download CCD File 
A
~{N}-[4-(4-azanyl-1-propan-2-yl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-methyl-phenyl]-4-[4-fluoranyl-3-(trifluoromethyl)phenyl]-4-oxidanylidene-butanamide
C26 H24 F4 N6 O2
QTIJDEKGLBXUPB-UHFFFAOYSA-N
 Ligand Interaction
PGF
Query on PGF

Download SDF File 
Download CCD File 
A
2,5,8,11-TETRAOXATRIDECANE
C9 H20 O4
JRRDISHSXWGFRF-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.13 Å
  • R-Value Free: 0.269 
  • R-Value Work: 0.209 
  • Space Group: P 61 2 2
Unit Cell:
Length (Å)Angle (°)
a = 82.027α = 90.00
b = 82.027β = 90.00
c = 172.609γ = 120.00
Software Package:
Software NamePurpose
PHENIXrefinement
PHENIXphasing
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Cancer Research UKUnited KingdomC24461/A23302
Medical Research Council (United Kingdom)United KingdomMR/K016903

Revision History 

  • Version 1.0: 2018-10-03
    Type: Initial release
  • Version 1.1: 2018-10-31
    Type: Data collection, Database references